ReviewThe role of HER3 in gastric cancer
Introduction
Gastric cancer is the second leading cause of cancer-related mortality worldwide and is the fourth most commonly diagnosed [1]. Although the incidence of gastric cancer has slightly declined in recent decades, there are still 56% of new cases in Eastern Asia, 41% in China, 11% in Japan estimating at 934,000 cases [2].
Most gastric cancer patients present at advanced stage or metastatic disease, however, based on current evidences, overall 5-year survival rates are approximately 30% [3] in the USA and are less than 45% for stage III gastric cancer, even in Japan [4], with median overall survival (OS) and median progression-free survival (PFS) being only 9–13 and 6–7 months [5], respectively, even with the implementation of chemotherapy for the patients with recurrent after surgery therapeutic regimens or the advanced stage disease.
Moreover, with the rapidly development of clinical therapy, traditional chemotherapy agents, which have a predominant effect on proliferating cells, lack an effective chemotherapeutic window, as they are unable to distinguish between rapidly normal cells and tumor cells [6]. With continuous research on gastric cancer molecular biology, molecular-targeted drugs appeared not only improve the efficacy of chemotherapy but also decrease the side effects of drugs, so that the treatment of advanced gastric cancer has entered a new era [7]. Targeted drugs antineoplastic therapies, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been application with confrontation of gastric cancer. EGFR family tyrosine kinases play a critical role in the development of gastric cancer [8]. Here, we attempt to summarize one of the EGFR family members, HER3, which has not clearly elaboration in gastric cancer.
Section snippets
Her3
There are four members in the HER family, HER1 (EGFR), HER2, HER3 and HER4, which share a common structure of an extracellular ligand-binding domain, a transmembrane domain and an intracytoplasmic tyrosine kinase domain [9], [10]. EGFR is a tyrosine kinase, which is evolutionarily ancient and widely expressed. What is more, additional three members ERBBs2-4, are highly homologous to EGFR and have all been observed in all kinds types of cancer cells [11]. The formation of homodimer or
The HER3 expression and gastric cancer
A functional crosstalk between HER3 and gastric carcinoma has been somewhat elusive until recently. As several studies reported, evidences have begun to emerge on the acquisition of HER3 overexpression, which is a predictor of prognosis. Hayashi et al. studied a total of 134 patients with primary gastric adenocarcinomas who underwent a surgical therapy. They reported that HER3 was highly overexpressed (59%, 79/116) in gastric cancer, and HER3 overexpression was significantly relevant with poor
Conclusion
HER3, as a mirror to the importance of HER2 in tumorigenesis of gastric cancers, has gained more and more attention. However, the prognostic value of HER3 in gastric cancer is controversial, consensus guidelines should be standardized. It will be another novel molecule for investigating the pathogenesis of gastric cancer and a new potent candidate for molecule-target therapy. In addition, HER3 combination with either HER2-targeted or MET inhibitor for resistance and response prediction may be
Disclosure of interest
The authors declare that they have no conflicts of interest concernig this article.
Acknowledgements
This work was partially supported by the Young Scientists Fund of the National Natural Science Foundation of China (81101798) and the Young Scientists Fund of the Natural Science Foundation of Hei Long Jiang Province, China (QC2010115). We are grateful to Tao Liu and Jun Wei Qin for carefully reading and significant suggestions on this manuscript.
References (45)
- et al.
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
J Ann Oncol
(2008) - et al.
Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations
Cancer Lett J
(2012) - et al.
Intracellular expression of the truncated extracecellular domain of c-erbB3/HER3
Cell Sign J
(2001) - et al.
Molecular cancer therapy: can our expectation be MET?
Eur J Cancer
(2008) - et al.
Frequent amplification of the c-met gene in scirrhous type stomach cancer
Biophys Res Commun
(1992) - et al.
Cancer therapy: can the challenge be MET?
Trends Mol Med J
(2005) - et al.
Global patterns of cancer incidence and mortality rates and trends
J. Cancer Epidermal Biomarkers Prev
(2010) - et al.
Epidemiology of gastric cancer in Japan
Postgrad. J. Med
(2005) - et al.
Cancer statistics CA Cancer
J. Clin
(2013) - et al.
Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry
J. Gastric. Cancer
(2013)
Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: future steps
J Mol Clin Oncol
Mechanisms of disease: oncogene addiction a rationale for molecular targeting in cancer therapy
J Nat Clin Pract Oncol
Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy
J Cancer
The ErbB signaling network: receptor heterodimerization in development and cancer
J EMBO
Common and distinct elements is cellular signaling via EGF and FGF receptors
J Sci
Molecular basis for sensitivity and acquired resistance to gefitinib in HER2 overexpression human gastric cancer cell lines derived from liver metastasis
Br J Cancer
Genetic predictors of MEK dependence in non-small cell lung cancer
Cancer Res J
Anti-EGFR antibody efficiently and specifically inhibits human TSC2/smooth muscle cell proliferation: possible treatment options for TSC and LAM
PloS One
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells
Cancer Res J
The ERBB3 receptor in cancer and cancer gene therapy
Cancer Gene Ther J
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
Proc Natl Acad Sci U S A
Efficient coupling with phosphatidulinositol 3-kinase, but not phospholipase C gamma or GTPase-acticating protein, distinguishes ErbB3 signaling from that og other ErbB/EGFR family members
Mol Cell Biol J
Cited by (18)
MiR-125a-5p inhibits cell proliferation, cell cycle progression, and migration while promoting apoptosis in head and neck cancers by targeting ERBB3
2021, Auris Nasus LarynxCitation Excerpt :It bears structural similarities with epidermal growth factor receptor (EGFR) and Erb-B2 receptor tyrosine kinase 2 (ErbB2); their distinctions mainly lie in the amino acid sequences in the intracellular tyrosine kinase domains and changes in catalytic sites. Noted, ERBB3 is known to activate signaling pathways, such as PI3K/AKT, Jak/Stat, and MEK/MAPK, while regulating the proliferation, differentiation, and migration of cells, as well as other cellular activities [20–23]. Overexpression or aberrant activation of ERBB3 has been found in many carcinomas, including ovarian, liver, gastric, and cervical cancer [24–27].
The oncogenic role of ubiquitin specific peptidase (USP8) and its signaling pathways targeting for cancer therapeutics
2021, Archives of Biochemistry and BiophysicsCitation Excerpt :Globally, gastric cancer (GC) is one of the most common malignancies occurring in males as 2nd position and females as 3rd position [54]. The proto-oncogene HER-3 (epidermal growth factor receptor 3) reported encoding protein ErbB3 (receptor tyrosine kinase 3) which is normally associated with membrane and reported as a major cause of GC leading to poor prognosis [55]. It is already known that the EGFR is deubiquitinated and stabilized by cleaved USP8 (activated form) leading to increase EGF mediated downstream signaling [7,10].
Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells
2019, European Journal of PharmacologyCitation Excerpt :c-MET pathway activation enhances cancer hallmarks such as cell proliferation, survival and invasion and has been associated with a poor clinical outcome in GAC patients (Anestis et al., 2018). Additionally, overexpression of HER family members is a potential factor of the development of resistance to MET inhibitors (Wang et al., 2014). On the other hand, MET overexpression is a potential factor of development of resistance to inhibitors of HER family members (Chen et al., 2012).
Evaluation of ITGA3 as a Biomarker of Progression and Recurrence in Papillary Thyroid Carcinoma
2022, Frontiers in OncologyUhrf2 promotes hepatocellular carcinoma progression by upregulating erbb3/ras/raf signaling pathway
2021, International Journal of Medical Sciences